Alzheimer’s disease is one of the most feared health conditions, especially as people grow older. It slowly damages memory, thinking, and daily functioning.
Over time, it can make it difficult for a person to recognize loved ones or take care of themselves.
Despite many years of research, scientists still do not have a cure, and treatment options remain limited.
Because of this, researchers are constantly looking for new ways to prevent or slow down the disease.
One surprising area of research involves a group of drugs that were not originally designed for the brain at all.
These are GLP-1 receptor agonists, which are commonly used to treat type 2 diabetes and, more recently, for weight loss.
A new study from Anglia Ruskin University, published in the journal Molecular and Cellular Neuroscience, has taken a closer look at these drugs.
The researchers reviewed 30 earlier studies that tested four different GLP-1 drugs: liraglutide, semaglutide, exenatide, and dulaglutide. These studies were mainly done in animals or cells, rather than in humans.
To understand why these drugs might help, it is important to know what happens in Alzheimer’s disease. In the brain, two harmful proteins build up over time. One is called amyloid-beta, which forms sticky clumps known as plaques. The other is called tau, which forms twisted fibers inside brain cells. These changes damage and eventually kill brain cells.
The review found that many of the studies showed positive results. In 22 of the studies, the drugs reduced levels of amyloid-beta. In 19 studies, they reduced harmful forms of tau. These results suggest that the drugs may help slow down or prevent the processes that lead to Alzheimer’s disease.
Among the four drugs, liraglutide was studied the most and showed the strongest and most consistent results. It reduced both amyloid-beta and tau in many cases. Semaglutide and dulaglutide also showed positive effects, although fewer studies were available for them. Exenatide showed mixed results, meaning it worked in some cases but not in others.
However, results from human studies are still limited. Only two clinical trials were included in the review. In one study, people took liraglutide for 26 weeks. The drug did not reduce amyloid levels or improve thinking ability, but it did help maintain how the brain uses glucose, which is important for brain function.
In another study, people took exenatide for 18 months. This study did not find clear changes in the main Alzheimer’s proteins in brain fluid, but it did show a reduction in amyloid-beta in small particles released by cells. These particles may be an early sign of disease, so this finding could still be important.
The researchers believe that these drugs may work in several ways. They may reduce inflammation in the brain, improve how brain cells respond to insulin, and change how harmful proteins are produced. These effects could help protect brain cells before serious damage occurs.
Looking at the overall findings, the results are promising but not yet conclusive. Most of the strong evidence comes from animal and cell studies, which do not always translate directly to humans. The human trials so far have not shown clear improvements in memory or thinking.
This suggests that these drugs may be more useful for prevention rather than treatment. In other words, they might work best before symptoms appear, rather than after the disease has already developed.
The study highlights the need for larger and longer human trials. These future studies will help determine whether these drugs can truly slow down or prevent Alzheimer’s disease in people.
In summary, this research offers an exciting possibility. Drugs already used for diabetes and weight loss may also help protect the brain. While more evidence is needed, this approach could open a new path in the fight against Alzheimer’s disease.
If you care about brain health, please read studies about how the Mediterranean diet could protect your brain health, and Omega-3 fats and carotenoid supplements could improve memory.
For more health information, please see recent studies about antioxidants that could help reduce dementia risk, and higher magnesium intake could help benefit brain health.
